{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:19:15Z","timestamp":1787062755890,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T00:00:00Z","timestamp":1606003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T00:00:00Z","timestamp":1606003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100010221","name":"Higher Education Commision, Pakistan","doi-asserted-by":"publisher","award":["NRPU 20-3425"],"award-info":[{"award-number":["NRPU 20-3425"]}],"id":[{"id":"10.13039\/501100010221","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00210-020-02021-x","type":"journal-article","created":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T09:02:41Z","timestamp":1606035761000},"page":"929-940","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Involvement of selective GABA-A receptor subtypes in amelioration of cisplatin-induced neuropathic pain by 2\u2019-chloro-6-methyl flavone (2\u2019-Cl-6MF)"],"prefix":"10.1007","volume":"394","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1087-4241","authenticated-orcid":false,"given":"Nasiara","family":"Karim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer","family":"Abdelhalim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobia Ahsan","family":"Halim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajmal","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouman","family":"Altaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waqar","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukhsana","family":"Ghaffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Al-Harrasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,22]]},"reference":[{"key":"2021_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejphar.2017.02.047","volume":"801","author":"S Akbar","year":"2017","unstructured":"Akbar S, Subhan F, Karim N, Aman U, Ullah S, Shahid M, Ahmad N, Fawad K, Sewell RDE (2017) Characterization of 6-methoxyflavanone as a novel anxiolytic agent: a behavioral and pharmacokinetic approach. Eur J Pharmacol 801:19\u201327","journal-title":"Eur J Pharmacol"},{"key":"2021_CR2","first-page":"2001","volume-title":"The molecular architecture of GABA-A receptors","author":"EA Barnard","year":"2001","unstructured":"Barnard EA (2001) The molecular architecture of GABA-A receptors. In: pharmacology of GABA and Glycine neurotransmission. In: M\u00f6hler HE (ed) The molecular architecture of GABA-A receptors. Springer, Berlin, p 2001"},{"key":"2021_CR3","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.pain.2007.08.013","volume":"136","author":"D Bouhassira","year":"2008","unstructured":"Bouhassira D, Lanteri-Minet M, Attal N, Laurent B, Touboul C (2008) Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 136:380\u2013387","journal-title":"Pain"},{"key":"2021_CR4","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1254\/jphs.CR0050020","volume":"100","author":"J-K Cheng","year":"2006","unstructured":"Cheng J-K, Chiou L-C (2006) Mechanisms of the Antinociceptive action of gabapentin. J Pharmacol Sci 100:471\u2013486","journal-title":"J Pharmacol Sci"},{"key":"2021_CR5","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nature01868","volume":"424","author":"JA Coull","year":"2003","unstructured":"Coull JA, Boudreau D, Bachand K, Prescott SA, Nault F, Sik A et al (2003) Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain. Nature. 424:938\u2013942","journal-title":"Nature."},{"key":"2021_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1744-8069-8-71","volume":"8","author":"L Deng","year":"2012","unstructured":"Deng L, Guindon J, Vemuri VK, Thakur GA, White FA, Makriyannis A et al (2012) The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB(2) receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy. Mol Pain 8:71","journal-title":"Mol Pain"},{"key":"2021_CR7","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1093\/neuonc\/nou048","volume":"16","author":"JR Deuis","year":"2014","unstructured":"Deuis JR, Lim YL, Rodrigues de Sousa S, Lewis RJ, Alewood PF, Cabot PJ et al (2014) Analgesic effects of clinically used compounds in novel mouse models of polyneuropathy induced by oxaliplatin and cisplatin. Neuro-oncology 16:1324\u20131332","journal-title":"Neuro-oncology"},{"key":"2021_CR8","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.neuropharm.2010.11.026","volume":"60","author":"A Di Lio","year":"2011","unstructured":"Di Lio A, Benke D, Besson M, Desmeules J, Daali Y, Wang ZJ et al (2011) HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain. Neuropharmacology. 60:626\u2013632","journal-title":"Neuropharmacology."},{"key":"2021_CR9","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1200\/JCO.1992.10.5.795","volume":"10","author":"RW Gregg","year":"1992","unstructured":"Gregg RW, Molepo JM, Monpetit VJ, Mikael NZ, Redmond D, Gadia M, Stewart DJ (1992) Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 10:795\u2013803","journal-title":"J Clin Oncol"},{"key":"2021_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/bs.apha.2014.10.007","volume":"72","author":"JR Hanrahan","year":"2015","unstructured":"Hanrahan JR, Chebib M, Johnston GA (2015) Interactions of flavonoids with ionotropic GABA receptors. Adv Pharmacol 72:189\u2013200","journal-title":"Adv Pharmacol"},{"key":"2021_CR11","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1126\/science.1094925","volume":"304","author":"RJ Harvey","year":"2004","unstructured":"Harvey RJ, Depner UB, Wassle H, Ahmadi S, Heindl C, Reinold H et al (2004) GlyR alpha3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science. 304:884\u2013887","journal-title":"Science."},{"key":"2021_CR12","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/WCO.0b013e3283311e13","volume":"22","author":"TS Jensen","year":"2009","unstructured":"Jensen TS, Madsen CS, Finnerup NB (2009) Pharmacology and treatment of neuropathic pains. Curr Opin Neurol 22:467\u2013474","journal-title":"Curr Opin Neurol"},{"key":"2021_CR13","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1016\/j.bcp.2011.09.002","volume":"82","author":"N Karim","year":"2011","unstructured":"Karim N, Gavande N, Wellendorph P, Johnston GA, Hanrahan JR, Chebib M (2011) 3-Hydroxy-2\u2032-methoxy-6-methylflavone: a potent anxiolytic with a unique selectivity profile at GABA(A) receptor subtypes. Biochem Pharmacol 82:1971\u20131983","journal-title":"Biochem Pharmacol"},{"key":"2021_CR14","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/j.1476-5381.2011.01604.x","volume":"165","author":"N Karim","year":"2012","unstructured":"Karim N, Curmi J, Gavande N, Johnston GA, Hanrahan JR, Tierney ML et al (2012) 2\u2032-Methoxy-6-methylflavone: a novel anxiolytic and sedative with subtype selective activating and modulating actions at GABA(A) receptors. Br J Pharmacol 165:880\u2013896","journal-title":"Br J Pharmacol"},{"key":"2021_CR15","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature06493","volume":"451","author":"J Knabl","year":"2008","unstructured":"Knabl J, Witschi R, Hosl K, Reinold H, Zeilhofer UB, Ahmadi S et al (2008) Reversal of pathological pain through specific spinal GABAA receptor subtypes. Nature. 451:330\u2013334","journal-title":"Nature."},{"key":"2021_CR16","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.pain.2008.10.015","volume":"141","author":"J Knabl","year":"2009","unstructured":"Knabl J, Zeilhofer UB, Crestani F, Rudolph U, Zeilhofer HU (2009) Genuine antihyperalgesia by systemic diazepam revealed by experiments in GABAA receptor point-mutated mice. Pain. 141:233\u2013238","journal-title":"Pain."},{"issue":"Pt 5","key":"2021_CR17","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/brain\/116.5.1017","volume":"116","author":"A Krarup-Hansen","year":"1993","unstructured":"Krarup-Hansen A, Fugleholm K, Helweg-Larsen S, Hauge EN, Schmalbruch H, Trojaborg W, Krarup C (1993) Examination of distal involvement in cisplatin-induced neuropathy in man. An electrophysiological and histological study with particular reference to touch receptor function. Brain. 116(Pt 5):1017\u20131041","journal-title":"Brain."},{"key":"2021_CR18","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-12-0926","volume":"12","author":"CS Lancaster","year":"2013","unstructured":"Lancaster CS, Sprowl JA, Walker AL, Hu S, Gibson AA, Sparreboom A (2013) Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics. Mol Cancer Ther 12:1537\u20131544","journal-title":"Mol Cancer Ther"},{"key":"2021_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.bcp.2012.10.023","volume":"85","author":"JJ Liu","year":"2013","unstructured":"Liu JJ, Kim Y, Yan F, Ding Q, Ip V, Jong NN, Mercer JFB, McKeage MJ (2013) Contributions of rat Ctr1 to the uptake and toxicity of copper and platinum anticancer drugs in dorsal root ganglion neurons. Biochem Pharmacol 85:207\u2013215","journal-title":"Biochem Pharmacol"},{"key":"2021_CR20","first-page":"972827","volume":"2015","author":"A Miri","year":"2015","unstructured":"Miri A, Sharifi-Rad J, Tabrizian K, Nasiri AA (2015) Antinociceptive and anti-inflammatory activities of Teucrium persicum Boiss. Extract Mice Sci 2015:972827","journal-title":"Extract Mice Sci"},{"key":"2021_CR21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1124\/pr.108.00505","volume":"60","author":"RW Olsen","year":"2008","unstructured":"Olsen RW, Sieghart W (2008) International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol Rev 60:243\u2013260","journal-title":"Pharmacol Rev"},{"key":"2021_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.4097\/kjae.2014.67.1.4","volume":"67","author":"HJ Park","year":"2014","unstructured":"Park HJ (2014) Chemotherapy induced peripheral neuropathic pain. Korean J Anesthesiol 67:4\u20137","journal-title":"Korean J Anesthesiol"},{"key":"2021_CR23","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1213\/ANE.0b013e31826e1007","volume":"116","author":"HJ Park","year":"2013","unstructured":"Park HJ, Stokes JA, Pirie E, Skahen J, Shtaerman Y, Yaksh TL (2013) Persistent hyperalgesia in the cisplatin-treated mouse as defined by threshold measures, the conditioned place preference paradigm, and changes in dorsal root ganglia activated transcription factor 3: the effects of gabapentin, ketorolac, and etanercept. Anesth Analg 116:224\u2013231","journal-title":"Anesth Analg"},{"key":"2021_CR24","doi-asserted-by":"crossref","unstructured":"Prieto-Mart\u00ednez FD, L\u00f3pez-L\u00f3pez E, Ju\u00e1rez-Mercado KE, Medina-Franco JL (2019) Computational drug design methods\u2014current and future perspectives. In silico drug design: Elsevier. p. 19\u201344","DOI":"10.1016\/B978-0-12-816125-8.00002-X"},{"key":"2021_CR25","doi-asserted-by":"crossref","unstructured":"Quint\u00e3o NLM, Santin JR, Stoeberl LC, Corr\u00eaa TP, Melato J, Costa R (2019) Pharmacological treatment of chemotherapy-induced neuropathic pain: PPAR\u03b3 agonists as a promising tool. Front Neurosci 13","DOI":"10.3389\/fnins.2019.00907"},{"key":"2021_CR26","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1124\/jpet.108.141994","volume":"327","author":"EJ Rahn","year":"2008","unstructured":"Rahn EJ, Zvonok AM, Thakur GA, Khanolkar AD, Makriyannis A, Hohmann AG (2008) Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J Pharmacol Exp Ther 327:584\u2013591","journal-title":"J Pharmacol Exp Ther"},{"key":"2021_CR27","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.bcp.2009.12.024","volume":"79","author":"L Ren","year":"2010","unstructured":"Ren L, Wang F, Xu Z, Chan WM, Zhao C, Xue H (2010) GABAA receptor subtype selectivity underlying anxiolytic effect of 6-hydroxyflavone. Biochem Pharmacol 79:1337\u20131344","journal-title":"Biochem Pharmacol"},{"key":"2021_CR28","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1212\/WNL.34.7.934","volume":"34","author":"RI Roelofs","year":"1984","unstructured":"Roelofs RI, Hrushesky W, Rogin J, Rosenberg L (1984) Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology. 34:934\u2013938","journal-title":"Neurology."},{"key":"2021_CR29","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/44579","volume":"401","author":"U Rudolph","year":"1999","unstructured":"Rudolph U, Crestani F, Benke D, Brunig I, Benson JA, Fritschy JM et al (1999) Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature. 401:796\u2013800","journal-title":"Nature."},{"key":"2021_CR30","doi-asserted-by":"crossref","unstructured":"Sang CS, Hayes KS (2006) Anticonvulsant medications in neuropathic pain. In: McMahon SB,\u00a0 K.\u00a0M, (eds) Wall and Melzack's Textbook of Pain. Elsevier","DOI":"10.1016\/B0-443-07287-6\/50037-0"},{"key":"2021_CR31","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2013.2813","volume":"309","author":"EML Smith","year":"2013","unstructured":"Smith EML, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, le-Lindqwister N, Gilman PB, Shapiro CL, Alliance for Clinical Trials in Oncology (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. J Am Med Assoc 309:1359\u20131367","journal-title":"J Am Med Assoc"},{"key":"2021_CR32","doi-asserted-by":"publisher","first-page":"11199","DOI":"10.1073\/pnas.1305321110","volume":"110","author":"JA Sprowl","year":"2013","unstructured":"Sprowl JA, Ciarimboli G, Lancaster CS, Giovinazzo H, Gibson AA, Du G et al (2013) Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci U S A 110:11199\u201311204","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021_CR33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1744-8069-5-9","volume":"5","author":"LE Ta","year":"2009","unstructured":"Ta LE, Low PA, Windebank AJ (2009) Mice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli. Mol Pain 5:9","journal-title":"Mol Pain"},{"key":"2021_CR34","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1002\/1097-0142(19841001)54:7<1269::AID-CNCR2820540707>3.0.CO;2-9","volume":"54","author":"SW Thompson","year":"1984","unstructured":"Thompson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer JC (1984) Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer. 54:1269\u20131275","journal-title":"Cancer."},{"key":"2021_CR35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/sj.bjc.6600002","volume":"86","author":"ME van der Burg","year":"2002","unstructured":"van der Burg ME, de Wit R, van Putten WL, Logmans A, Kruit WH, Stoter G et al (2002) Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer. Br J Cancer 86:19\u201325","journal-title":"Br J Cancer"},{"key":"2021_CR36","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/bjc.1990.135","volume":"61","author":"RL Woods","year":"1990","unstructured":"Woods RL, Williams CJ, Levi J, Page J, Bell D, Byrne M, Kerestes ZL (1990) A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 61:608\u2013611","journal-title":"Br J Cancer"},{"key":"2021_CR37","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.intimp.2007.07.009","volume":"8","author":"HU Zeilhofer","year":"2008","unstructured":"Zeilhofer HU (2008) Loss of glycinergic and GABAergic inhibition in chronic pain--contributions of inflammation and microglia. Int Immunopharmacol 8:182\u2013187","journal-title":"Int Immunopharmacol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-020-02021-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-020-02021-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-020-02021-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T20:08:45Z","timestamp":1620331725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-020-02021-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,22]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["2021"],"URL":"https:\/\/doi.org\/10.1007\/s00210-020-02021-x","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,22]]},"assertion":[{"value":"27 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}